Activity of pyocin S2 against Pseudomonas aeruginosa biofilms by Smith, K et al.
Activity of Pyocin S2 against Pseudomonas aeruginosa Biofilms
Karen Smith, Laura Martin, Angela Rinaldi, Ranjith Rajendran, Gordon Ramage, and Daniel Walker
Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
In cystic fibrosis patients, chronic lung infection with Pseudomonas aeruginosa and the associated decline in lung function are
the major cause of mortality. In this report, we show that pyocin S2 displays potent activity against P. aeruginosa biofilms, thus
representing a potentially improved therapeutic option. Using an invertebrate model of P. aeruginosa infection, we also show
that pyocin S2 is highly active in vivo.
Due to the increasing prevalence of multidrug-resistantpathogenic bacteria and the poor efficacy of existing treat-
ments against chronic bacterial infection, there is a critical re-
quirement for the development of novel classes of antibiotics
(4, 14). This is exemplified in cystic fibrosis (CF) patients, for
whom, despite aggressive antibiotic therapy, chronic lung in-
fection with P. aeruginosa and the concomitant intense inflam-
matory response leads to a progressive loss of lung function
and is the major proven cause of mortality among this group of
patients (8, 11).
An alternative strategy for antibiotic discovery is to utilize
the narrow-spectrum antibiotics used by bacteria for intraspe-
cies competition. In Gram-negative bacteria, these often take
the form of high-molecular-weight protein antibiotics known
as bacteriocins (6, 7, 13). In this report, we show that pyocin S2
displays potent activity in vitro against clinical isolates of P.
aeruginosa growing in the biofilm state. Further to this, pyocin
S2 is highly active in an invertebrate model of P. aeruginosa
infection.
P. aeruginosa grows predominantly as a biofilm in the CF-
infected lung, and this state is associated with high levels of resis-
tance to small-molecule antibiotics (6, 9). To determine if pyocins
display potent activity against P. aeruginosa growing in the biofilm
state, we first cloned the genes for pyocin S2 (2) and its immunity
protein ImS2 into an Escherichia coli expression vector and ex-
pressed and purified the protein in complex with its immunity
protein.
The pyocin S2-ImS2 complex was isolated by nickel affinity
chromatography by virtue of an engineered C-terminal His6 tag
on the immunity protein (Fig. 1a). The purified pyocin S2-ImS2
complex was highly active against P. aeruginosa growing on LB
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FIG 1 Purification of S-type pyocins and killing activity of the pyocin S2-Im2 complex against P. aeruginosa. (a) SDS-PAGE of purified pyocin S2-ImS2 complex
(lane 1). (b) Activity of purified pyocin S2-ImS2 against P. aeruginosa. A 5-fold serial dilution (starting concentration, 2 mg/ml [top left]) of pyocin S2-ImS2 was
spotted onto a lawn of growing P. aeruginosa strain YHP17 which was grown overnight at 37°C. Clear zones indicate cell death. (c) Activity of pyocin S2-ImS2
against P. aeruginosa biofilms. Biofilms (24 h) of P. aeruginosa YHP14 were grown on poly-L-lysine glass cover slides, treated with a pyocin S2 at 3 g/ml and 64
g/ml for 1 h, and visualized by fluorescence microscopy using LIVE/DEAD cell viability staining. Red, dead cells; green, live cells.
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agar (Fig. 1b). We initially tested the activity of pyocin S2 against
biofilms formed by P. aeruginosa isolate YHP14 treated with a
single dose of pyocin S2 for 1 h at 3 g/ml and 64 g/ml and
visualized by fluorescence microscopy using LIVE/DEAD cell vi-
ability staining (Fig. 1c). Parallel biofilm killing assays were also
performed for tobramycin and aztreonam, approved antibiotics
for treatment of chronic CF lung infection by inhalation (12).
From the relative number of live (green) and dead (red) cells, it is
apparent that pyocins are highly active against P. aeruginosa in the
biofilm state, killing a larger proportion of cells than either tobra-
mycin or aztreonam at equivalent concentrations (Fig. 1c).
To obtain quantitative data on the ability of pyocins to kill P.
aeruginosa biofilms, we treated YHP14 24-h biofilms, grown on
the plastic pegs of the MBEC biofilm cultivation system, with pyo-
cin S2, tobramycin, and aztreonam (0.001 to 390 g/ml) for 1 h
(Fig. 2). Cells were removed by sonication, and colonies were
counted by plating serial dilutions of recovered cells on solid me-
dia. The ability of YHP14 to form structured multilayered biofilms
FIG 2 Biofilm-associated survival of P. aeruginosa strains YHP14, YHP15, and YHP7 after treatment with pyocin S2, aztreonam, or tobramycin. Upper panels
show 24-h biofilms from each strain visualized by scanning electron microscopy. Lower panels show the percent survival after a single treatment with pyocin
S2-ImS2, aztreonam, or tobramycin (0.001 g/ml to 390 g/ml) for 1 h. Error bars represent the standard deviations between replicate samples (n  6). All P.
aeruginosa clinical isolates were collected from sputum samples from children with cystic fibrosis at the Royal Hospital for Sick Children (Yorkhill, Glasgow,
United Kingdom). P. aeruginosa biofilms were formed on an MBEC 96-peg plate platform (Innovotech, Edmonton, Canada), as previously described (1).
FIG 3 Ability of pyocin S2-ImS2 to provide protection against a lethal P. aeruginosa infection in the Galleria mellonella caterpillar. (a) Survival plot for groups
of larvae infected with P. aeruginosa YHP14 and treated with pyocin S2-ImS2. Groups of 20 larvae were not infected or were inoculated with 104 CFU of P.
aeruginosa YHP14 and after 3 h were injected with either PBS (control) or pyocin S2 (27 mg/kg). (b) Lethal infection by P. aeruginosa is accompanied by the
generation of melanin in larvae leading to a distinct change in color from cream to dark brown in larvae close to death. Shown are larvae infected with YHP14 and
treated with pyocin S2-ImS2 (top) or with PBS (bottom). Infection of Galleria mellonella larvae (Livefood, United Kingdom) was performed as previously
described (5).
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under these conditions was first confirmed by electron micros-
copy (Fig. 2). In this assay, pyocin S2 was found to kill P. aerugi-
nosa in the biofilm state considerably more effectively than aztreo-
nam or tobramycin, with S2-treated biofilms showing a reduction
of close to 4 log units in cell survival at the highest concentration of
antibiotic tested.
Since clinical isolates of P. aeruginosa are phenotypically di-
verse, in particular in terms of the level of production and incor-
poration of extracellular polysaccharide into the biofilm matrix,
we compared the activity of pyocin S2 against isolates with differ-
ent levels of mucoidy (Fig. 2). Despite different levels of extracel-
lular polysaccharide production, the level of killing of pyocin S2
against YHP15 and YHP7 biofilms was remarkably similar to that
shown against YHP14 and in all cases was greater than the level of
killing shown by tobramycin and aztreonam. At an antibiotic con-
centration of 3 g/ml, cell survival of pyocin S2-treated YHP7
biofilms was 0.3%, with tobramycin- and aztreonam-treated bio-
films showing 100-fold increased survival rates of 30% and 60%,
respectively.
To determine if pyocins are active during infection, we tested
the ability of pyocin S2 to provide protection against a lethal P.
aeruginosa infection in a whole animal. For this purpose, we chose
a nonvertebrate host, the Galleria mellonella caterpillar, in which
P. aeruginosa has been shown to be highly virulent and in which
pathogenesis is dependent on similar virulence factors that are
essential for pathogenesis in mammals (10). Groups of 20 larvae
were inoculated with 104 CFU of YHP14 and after 3 h injected
with either phosphate-buffered saline (PBS) (control) or pyocin
S2 (27 mg/kg). The larvae were monitored every 2 h between 10
and 72 h. Those in the control group (PBS injected after inocula-
tion) died 12 to 14 h postinfection, while those treated with pyocin
S2 postinfection survived until the experiment was stopped at 72 h
(Fig. 3a). Lethal infection by P. aeruginosa is accompanied by the
generation of melanin in larvae, leading to a distinct change in
color from cream to dark brown in larvae close to death (note light
and dark larvae in Fig. 3b). Larvae in additional control groups
that were not infected with P. aeruginosa but were treated with
PBS or pyocin also survived until the end of the experiment, indi-
cating that pyocin S2 is not toxic to the host in the absence of
infection (Fig. 3a). Colony counts from larvae confirmed that the
PBS-only and pyocin-only controls contained no P. aeruginosa.
The group that was infected with strain YHP14 contained between
5  108 and 1  109 CFU at time of death. The infected group
treated with pyocin contained between 10 and 40 CFU.
In this report, we have shown that pyocin S2 has potent activity
against P. aeruginosa growing in the biofilm state and is capable of
protecting against a lethal P. aeruginosa infection. In infections
where the microbiology of infection is closely monitored, species-
specific protein antibiotics may provide a useful therapeutic op-
tion.
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